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Abstract
Background: Neoadjuvant chemotherapy is a standard of care for patients with adenocarcinoma of the esophagus
and stomach in Europe, but still only 20–40 % respond to therapy and the critical issue; how to treat
nonresponding patients is still unclear. So far, there is no randomized trial evaluating the impact of early
termination of neoadjuvant chemotherapy and immediate tumor resection in nonresponding patients with
locally advanced gastroesophageal cancer on postoperative outcome. With this exploratory pilot trial, we want
to get first estimates about the effect of discontinuation of chemotherapy with the aim to plan and conduct
a further definitive trial.
Methods/design: OPTITREAT is designed as a single-center, randomized controlled pilot trial with two parallel study
groups. Four weeks after starting neoadjuvant chemotherapy in all patients, clinical response will be assessed by
endoscopy and endosonographic ultrasound. Then, nonresponding patients (n = 84) will be randomized in a 1:1
ratio to intervention group with stopping chemotherapy and immediate tumor resection or control group with
completion of chemotherapy before surgery. Outcome measures are overall survival, R0 resection rate, perioperative
morbidity and mortality, histopathological response, and quality of life. Statistical analysis will be based on the
intention-to-treat population. Due to the study design as an explorative pilot trial, no formal sample size calculation
was performed. The planned total sample size of 120 patients is considered ethical and large enough to show the
feasibility and safety of the concept. First data on differences between the study groups in the defined endpoints will
also be generated.
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Discussion: Individualized therapy is of utmost interest in the treatment of locally advanced gastroesophageal
adenocarcinoma as less than half of the patients show objective response to current chemotherapy regimens. The
findings of the OPTITREAT trial will help to get first data about clinical response evaluation followed by immediate
tumor resection in nonresponding patients after 4 weeks of neoadjuvant chemotherapy. Based on the results of this
pilot study, a future confirmatory trial will be planned to prove efficacy and evaluate significance.
Trial registration: German Clinical Trial Register number: DRKS00004668
Keywords: Esophagogastric cancer, Neoadjvuant chemotherapy, Response evaluation
Background
Rationale and preliminary data
Based on a recent meta-analysis [1] and three randomized
trials [2–4], standard treatment for locally advanced gas-
troesophageal adenocarcinomas consists of perioperative/
neoadjuvant chemotherapy or alternatively preoperative
radiochemotherapy for tumors of the gastroesophageal
junction. Perioperative chemotherapy demonstrated a sur-
vival benefit of about 13 % after 5 years for patients with
adenocarcinoma of the esophagus or stomach. However, it
is generally accepted that patients with initially locally ad-
vanced tumors who respond to chemotherapy have excel-
lent 5-year survival rates of up to 70 % [5] whereas
nonresponding patients have significantly worse survival
rates of 15–30 % [6, 7]. Some authors even suggest that
nonresponding patients could have a worse prognosis [8],
lower complete resection rates [9], and an increased mor-
bidity after chemotherapy compared to primarily resected
patients. Especially for patients with esophageal cancer,
there is evidence that nonresponding patients tend to have
a higher perioperative complication rate and a higher
mortality [10]. Additionally, only 25–50 % of the patients
respond to neoadjuvant chemotherapy [5–7] depending
on the applied chemotherapy regimen and the type of re-
sponse evaluation applied. The need for individualized
therapy regimens for patients with gastroesophageal
adenocarcinomas is obvious. Until now, it has not been
possible to predict response to chemotherapy by molecu-
lar markers and to select those patients who benefit from
neoadjvuant chemotherapy pretherapeutically [11–18].
Therefore, the evaluation of nonresponding patients at
least early during preoperative treatment with the possi-
bility to adapt the further therapy would be of utmost
interest. Stopping an ineffective therapy would avoid
toxicity, costs, and a decreased quality of life due to sec-
ondary effects of the chemotherapy.
Aims and objective
The primary objective of the OPTITREAT trial is to get
first data about early termination of neoadjuvant chemo-
therapy in nonresponding patients with locally advanced
gastroesophageal cancer.
With this exploratory pilot trial, we want to get initial
estimates of survival of the study population as well as
response rates during chemotherapy for being able to
plan a definitive trial. Furthermore, we want to deter-
mine whether stopping treatment has any unforeseen
detrimental effects on the patients with respect to short-
and long-term survival as well as if there are any unfore-
seen risks by stopping chemotherapy resulting in a higher
perioperative morbidity and or mortality. Additionally, we
want to get first data about the influence of discontinuation
of chemotherapy on quality of life.
Methods/design
Study population and eligibility criteria
The study population consists of all patients with histo-
logically proven, resectable gastroesophageal adenocar-
cinoma who are staged cT2/3/4 and/or cN+ by
endoscopy, endoscopic ultrasound, and computerized
tomography (CT) scan and thereby meet the criteria and
clinical condition for neoadjuvant/perioperative chemo-
therapy. Patients will be informed about the purpose of
the trial, potential benefits, and risks at the Department
of General, Visceral and Transplantation Surgery of the
University of Heidelberg or at the Department of Med-
ical Oncology at the National Center for Tumor Dis-
eases Heidelberg (NCT). Screening and information will
be organized and overviewed by the Clinical Study Cen-
ter, Heidelberg. If an informed consent is given and all
inclusion criteria are fulfilled and exclusion criteria are
adhered to (Table 1), patients will be included into the
trial. After inclusion, all patients will receive neoadjuvant
chemotherapy and 4 weeks after the first day of chemo-
therapy, patients will undergo endoscopy and endo-
scopic ultrasound to assess clinical response. Patients
who were screened but not enrolled in the trial will be
documented in the screening log and the reason for ex-
clusion will be recorded.
Sample size
The number of eligible patients will be 120, and among
them, the number of patients meeting the criteria for
nonresponse is estimated to be 84 assuming a response
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rate of 30 % [3, 5, 6, 19]. Thus, 42 nonresponding pa-
tients per group are estimated to be randomized. To
reach that number, a total of 200 patients with locally
advanced carcinoma of the esophagus or stomach are es-
timated to be assessed for eligibility (Fig. 1).
Trial design
The OPTITREAT trial is designed as a single-center, ex-
plorative, randomized controlled pilot trial with two par-
allel study groups.
Recruitment and trial timeline
Patient recruitment started in September 2014 and is ex-
pected to be as long as 24 months. The follow-up period
is 30 months and total duration of the trial is estimated
to be 6 years including analysis.
Randomization
After undergoing clinical response evaluation (see
below), all patients defined as nonresponders will be al-
located to one of the two treatment arms. In order to
achieve comparable study groups, patients will be ran-
domly assigned 1:1 to interventional or control group
using block randomization and applying a central online
randomization system (randomizer.at).
Interventions and examinations
All patients will receive neoadjuvant chemotherapy for
at least 4 weeks. Neoadjuvant chemotherapy should in-
clude a platinum compound and a fluoropyrimidine ac-
cording to the data from the MAGIC trial [3] and the
French ACCORD 07 trial [2]; optionally, a taxane or an
anthracycline will be chosen by the oncologist according
to local standards and in consideration of patient’s per-
formance status and comorbidities.
Table 2 summarizes the possible chemotherapy
schedules.
Before starting chemotherapy, endoscopy and endo-
scopic ultrasound as well as CT scan will be performed
to obtain initial clinical tumor staging according to the
TNM Classification for Malignant Tumors, 7th edition
(2010). Endoscopy and endoscopic ultrasound will be re-
peated 4 weeks after the beginning of chemotherapy, i.e.,
on days 12–14 of cycle 2 in case of a 2-week protocol or
on days 5–7 of cycle 2 in case of a 3-week protocol.
Clinical response will be assessed during the second en-
doscopy according to defined criteria (Table 3), which
have already been shown to be of prognostic relevance
[20–22]. Video/digital image documentation will be
done to compare the initial diagnostic findings with the
following examinations 4 weeks later.
In case of delay of the second chemotherapy cycle,
e.g., because of side effects, cytopenia, or other causes,
clinical response evaluation will be performed on days
12–14 and days 5–7 of the second cycle, respectively.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Histologically proven adenocarcinoma of the esophagus or stomach
Clinical staging cT3/4 and/or cN+
Resectable primary tumor
Patient considered to tolerate chemotherapy as well as surgery
≥18 years of age
Written informed consent
Exclusion criteria
Lack of understanding or language problems
Expected lack of compliance
Patients not eligible for surgery (ASA≥ IV)
Distant metastases (M1) without possibility of complete resection (R0)
Neoadjuvant radiochemotherapy
ASA American Society of Anaesthesiologists classification
Fig. 1 Study Flow Chart
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In patients with clinical response, neoadjuvant therapy
will be completed to a total of 4 cycles in case of a 2-
week protocol or to a total of 3 cycles in case of a 3-
week protocol. Clinical nonresponders will be random-
ized to one of the two following study groups:
Experimental intervention
Neoadjuvant chemotherapy will be stopped after 4 weeks,
and tumor resection will be performed between 1 and
3 weeks after termination of chemotherapy.
Control intervention
Neoadjuvant chemotherapy will be completed as
intended in the respective chemotherapy regimen, and
tumor resection will be performed between 1 and
3 weeks after the end of chemotherapy.
Tumor resection will be done according to the local
standards of the center. Surgery will be open access sur-
gery. In patients with adenocarcinoma of the esophago-
gastric junction (AEG) I/(II), either an Ivor Lewis
procedure, i.e., abdominothoracic approach with intra-
thoracic anastomosis, including a two-field lymphade-
nectomy or a transhiatal esophagectomy with cervical
anastomosis will be performed. Both procedures include
an abdominal D-2 lymphadenectomy. Patients with type
(II)/III tumors will undergo a transhiatal extended gas-
trectomy and an extended D2-lymphadenectomy, i.e., re-
section of the lymph node groups 1 and 2 according to
the Japanese Research Society for Gastric Cancer. In pa-
tients with tumor localization in the middle or distal
third of the stomach and for distal gastric tumors, a total
gastrectomy with D2-lymphadenectomy and a subtotal
gastrectomy including a D2-lymphadenectomy, if an ad-
equate proximal resection margin is possible, will be per-
formed, respectively.
Permitted and not permitted medications/treatments
The administered chemotherapy protocol including dose
reduction, stopping, and delay of administration of
chemotherapy will be monitored during the whole study.
During the postoperative course, adjuvant chemotherapy
will not be changed.
Concomitant supportive therapy, e.g., antiemetics, hy-
dration, blood transfusions, and hematopoetic growth
factors, will be applied according to the local standards
of the center. Toxicities requiring dose adjustment, ter-
mination, or switch of the whole protocol or of single
chemotherapy agents will be managed according to the
choice of the investigator.
Any protocol violation will be documented in the case
report form (CRF).
Risks
For clinical response evaluation, all patients included in
the trial will undergo a second endoscopy and endo-
scopic ultrasound examination, which are no standard
procedures outside the trial. These examinations go
along with a potential risk of associated complications,
e.g., teeth trauma, bleeding of the mucosal layer, perfor-
ation of the esophagus or stomach with possible indica-
tion for urgent surgery, postinterventional dysphagia,
and allergic reactions as well as complications due to the
analgosedation. Patients will be informed about these
complications before inclusion as well as at least 24 h
before each intervention. Besides this, no additional risks
are expected for participants.
Outcomes and assessment
The following outcome measures will be assessed:
Table 3 Criteria for clinical response evaluation [20–22]
Endoscopy Endoscopic ultrasound Others
Responder Major reduction of tumor size (>75 %)
with significant flattening of the tumor
and More than 50 % reduction of wall thickness
(at the largest tumor diameter)
– –
Nonresponder Visible residual tumor and/or Less than 50 % reduction of wall thickness
(at the largest tumor diameter)
and/or Metastatic lesions
Table 2 Chemotherapy schedules
2-week protocols
FLOT FLO
Docetaxel 50 mg/m2 1 h d
(day)1
Oxaliplatin 85 mg/m2 2 h d1
Oxaliplatin 85 mg/m2 2 h d1 Folic acid 200 mg/m2 2 h d1
Folic acid 200 mg/m2 2 h d1 5-Fluorouracil 2600 mg/m2 24 h
d1repeat d 15
5-Fluorouracil 2600 mg/m2
24 h d1repeat d 15
3-week protocols
ECF ECX
Epirubicin 50 mg/m2 push d1 Epirubicin 50 mg/m2 push d1
Cisplatin 60 mg/m2 2 h d1 Cisplatin 60 mg/m2 2 h d1
5-Fluorouracil 200 mg/m2 24 h
d1–21repeat d 22
Capecitabine 625 mg/m2 2×/d
p.o. d1–21repeat d 22
EOF EOX
Epirubicin 50 mg/m2 push d1 Epirubicin 50 mg/m2 push d1
Oxaliplatin 130 mg/m2 2 h d1 Oxaliplatin 130 mg/m2 2 h d1
5-Fluorouracil 200 mg/m2 24 h
d1–21repeat d 22
Capecitabine 625 mg/m2 2×/d
p.o. d1–21repeat d 22
Blank et al. Pilot and Feasibility Studies  (2016) 2:18 Page 4 of 10
Overall survival: the time from the day of
randomization to the day of death due to any
reason. After randomization, patients will be
followed up for a minimum duration of 30 months
or until death. Patients who have not died by the
end of follow-up will be censored at their last con-
tact date, as will be those patients who will be with-
drawn from the study for a reason other than death
(e.g., lost to follow-up).
Rate of complete tumor resection (R0 resection rate):
the frequency of R0 resections as stated in the
histology report.1
Perioperative morbidity: the frequency and type of
perioperative complications as defined in Table 4
from the day of surgery until 3 months after the
index operation.
Perioperative mortality: the frequency of deaths due
to any reason occurring within 30 days after surgery
or within the initial hospital stay for resection of the
primary tumor.
Clinical response: as described above and defined in
Table 2.
Histopathological response: the histopathological
tumor regression will be assessed using the Becker
regression score compromising four tumor
regression grades: 1a—no residual tumor, 1b—<10 %
viable tumor, 2—10–50 % viable tumor, and
3—>50 % viable tumor [23]. According to Becker’s
Table 4 Definitions of postoperative morbidity
Anastomotic leakage Loss of integrity of the anastomosis, confirmed by appearance of contrast medium outside the anastomosis in the
abdominal or pleural cavity after oral ingestion of contrast medium or by endoscopy
Leakage of the duodenal
stump
Loss of integrity of the duodenal stump leading to diffusion of bile and pancreatic juice to the abdominal cavity
Pancreatic fistula Drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3
times the serum amylase activity
Classification (according to the ISGPS definition):
Grade A: clinically not apparent, well condition, no infectious signs
Grade B: infectious sign but no sepsis, persistent drainage, no reoperation
Grade C: sepsis and/or reoperation necessary
Postoperative
hemorrhage
Drop of systemic hemoglobin ≥3 g/dl compared to postoperative baseline level and/or need for transfusion of >2 units
of packed red blood cells due to intraabdominal hemorrhage as indicated by blood loss via the abdominal drains and/or
interventional treatment
Abscess Closed collection of pus in the abdominal or pleural cavity
Wound healing problems Leading to the necessity of a special wound care
Lymph fistula Caused by damage of a lymphatic duct, leading to diffusion of chylus in the abdominal cavity. Diagnosis is done by
measurement of triglyceride level in the abdominal drain. A triglyceride level three times higher than serum level is
defined as lymphatic fistula.
Chylothorax Accumulation of chylus in the thoracic cavity caused by damage of the thoracic duct or other intrathoracal lymphatic
ducts
Tracheal lesions Fistulas between esophagus and trachea, as well as loss of integrity of the tracheal wall
Deep vein thrombosis Formation of a new thrombus in a deep vein, clinically evident (swollen/livid leg, pain), verified by Doppler ultrasound or
CT angiography
Pulmonary embolisms Emboli in the main pulmonary artery or its branches, clinically evident (tachypnea, tachycardia) and verified by CT
angiography
Pulmonary infection At least 3 of 4 of the following:
Temperature >37.5 °C
Purulent tracheal secretion
White blood count >12,000 or <4500/ml
Elevated CRP level
As well as radiological evidence of pulmonary infection
Renal failure Renal failure of sudden onset after operation: doubling of preoperative serum, creatinine level, or need for dialysis or
hemofiltration (in patients who were not on dialysis preoperatively)
Cerebral insult Acute cerebral hypoperfusion, clinically evident by neurological symptoms, verified by cerebral CT scan and/or CT
angiography
Myocardial infarction Clinical symptoms of myocardial infarction as well as heart enzyme (troponin T) changes suggestive of myocardial
infarction, changes in electrocardiogram for STEMIs, or evidence of myocardial infarction on coronary angiogram
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suggestion, regression scores 1a and 1b both indicate
response, whereas regression scores 2 and 3 indicate
nonresponse.1
Quality of life: the EORTC QLQ-C30 instrument
and the specific esophagogastric module EORTC
QLQ-OG25 will be used to assess patients’ quality
of life.
Study visits
From screening day to day of discharge, there will be five
study visits assessing baseline data and demographics,
eligibility criteria, endoscopic findings and clinical re-
sponse, randomization, surgical procedure including re-
section status and histopathological response, and
perioperative morbidity and mortality as well as details
of chemotherapy, quality of life, and safety (Table 5).
After discharge from hospital, treating oncologists as
well as patients will be contacted by phone and in writ-
ten form to obtain follow-up data every 3 months during
the first year after surgery, every 6 months during the
second year and once per year afterwards until death or
end of study.
Safety evaluations and reporting of adverse events
The incidence of all serious adverse events (SAEs) that
occur from the day of inclusion until study termination
will be closely monitored and evaluated. A SAE is
defined as any adverse event occurring at any time dur-
ing the period of observation that results in death, is
immediately life-threatening, requires, or prolongs
hospitalization, results in persistent or significant disabil-
ity or incapacity, and/or requires medical or other inter-
vention to prevent permanent impairment or damage.
All SAEs will be documented on specific SAE forms,
and a detailed description of the SAE including the type
of event, treatment and seriousness of SAE, causality to
trial intervention, outcome, and end of SAE will be
given. Postoperative complications which are docu-
mented as endpoints in the CRF will not be reported as
SAE.
Data and safety monitoring board
A data and safety monitoring board (DSMB) composed
of independent experts was established before starting
the trial. In case of any irregularities, e.g., concerning the
frequency or type of reported SAE, the principal investi-
gator will inform the members of the DSMB without
delay. Every 20 randomized patients, the DSMB will re-
ceive a written safety report. Then, the members of the
DSMB will evaluate the benefit/risk ratio and will give
appropriate recommendations concerning the continu-
ation of the trial.
Statistical methods
Sample size calculation
Due to the study design as an explorative pilot trial, no
formal sample size calculation was performed. A total of
84 nonresponding patients are estimated to be random-
ized in a 1:1 ratio using block randomization. Since re-
sponse status of the individual patient cannot be defined
at the initial stage of the trial, 120 patients in total will
have to be included assuming a response rate of 30 %.
The formal sample size is chosen to get a reasonable
number of patients in the intended recruitment timeline
of 2 years.
Statistical analysis
The statistical analysis will be of descriptive nature, the
resulting p values will not have any confirmative value.
Statistical methods will be used to assess the quality of
data, homogeneity of treatment groups, endpoints, and
safety of the three treatment groups. The analysis will be
performed on the basis of an intention to treat (ITT)
population and with respect to ITT principles. A patient
belongs to the ITT population, when the patient was
found to be suitable for the study, signed the informed
consent, and finishes the first part of initial chemother-
apy. As sensitivity analysis, the endpoints will also be an-
alyzed on the basis of the per protocol (PP) population,
where all patients are enclosed, which will finish the trial
without protocol deviations
Baseline characteristics, efficacy, and safety endpoints
will be analyzed with descriptive methods. The descrip-
tion of continuous variables will include at least the
number of observations, mean, 95 % confidence inter-
vals, standard deviation, and median as well as minimum
and maximum in the trial population. The description of
categorial variables will include at least the number and
percentage (including 95 % confidence intervals) of pa-
tients belonging to the relevant categories in the trial
population as well as in each treatment group.
Possible differences between the two groups of nonre-
sponding patients will be tested for outcome measures
using t test in case of continuous variables and with chi-
square test in case of categorical variables. Possible dif-
ferences in overall survival will be assessed using
Kaplan-Meier method including log-rank test. As stated
above, these tests are of descriptive nature without any
confirmatory value.
Documentation and data handling
The investigator or a designated representative will
complete the CRF for the documentation of all protocol-
required information. After completing the CRF, it will
be reviewed and signed by the investigator and sent to
the Institute of Medical Biometrics and Informatics
(IMBI), University of Heidelberg. The IMBI will be in
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Table 5 Study visits in the OPTITREAT trial
Documentation Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 FU FU FU FU FU FU FU
Screening Before CTx 4 weeks after CTx Before surgery Discharge 3 months 6 months 9 months 12 months 18 months 24 months 30 months
Baseline data, demographics X
Eligibility criteria X
Endoscopy X X
Clinical response X
Randomization X
Quality of life X X X
Information about CTx X
R0 resection X
Histopathological response X
Information about surgery X
Perioperative morbidity X X
Perioperative mortalitiy X X
Severe adverse events X X X X X
Survival analysis/recurrence X X X X X X X
CTx chemotherapy, FU follow-up
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charge of the data management within the trial. All data
management procedures will be carried out according to
the current standard operating procedures (SOPs) of the
IMBI.
Clinical monitoring will be performed by the Study
Center of the German Surgical Society (SDGC).
Withdrawals
Subjects will be free to withdraw their consent at any
time without providing a specific reason and without
any disadvantage for them. In case of withdrawal, pa-
tients will be asked if they agree to be included in the
analysis till the point of withdrawal or if they should be
taken completely out of the analysis and data should be
destroyed.
Subject information and informed consent
Patients will be informed about the trial including the
procedures, possible hazards to which the individual pa-
tient will be exposed as well as the mechanism of treat-
ment allocation in oral and written form. After reading
the information form and having been explained the trial
including its consequences in an understandable form,
the individual patients will have to give written consent
to participate in the trial. No interventions or measure-
ments in relation to the trial will be made before.
Ethical and legal aspects
Approval
Prior to the start of the trial, the protocol was presented
to the independent ethics committee of the University of
Heidelberg and written approval was obtained on
16.07.2013 (reference number: S-637/2012).
Good clinical practice
This trial is accomplished in conformity with the princi-
pals of the Declaration of Helsinki and the Guidelines
for Good Clinical Practice in their current revision. The
trial will be carried out in keeping with national and
international legal and regulatory requirements.
Registration
The trial protocol has been registered with the German
Clinical Trials Register (DRKS; DRKS00004668).
Discussion
Individualized therapy regimens for patients with gastro-
esophageal adenocarcinomas are more and more re-
quested as response rates and prognosis are not
satisfying. Until now, it has not been possible to predict
response to chemotherapy by molecular markers and to
select those patients who benefit from neoadjvuant
chemotherapy pretherapeutically [11–18].
Therapy monitoring with positron emission tomog-
raphy using F-18fluorodeoxyglucose (FDG-PET) after
2 weeks of chemotherapy has only been evaluated for
AEG I and II in clinical trials and cannot be transferred
to clinical routine due to a lack of multicentric valid-
ation. Additionally, the value of FDG-PET for response
evaluation in gastric cancer is clearly limited, since in
50 % of the patients with diffuse gastric cancer tumors
do not uptake FGD [20] and data on prognosis are rare
and inconclusive [24]. However, the unicentric MUNI-
CON I trial [9] showed for the first time the feasibility
of a PET-guided treatment algorithm after only 2 weeks
of chemotherapy. In nonresponding patients, chemo-
therapy was stopped after 2 weeks and these patients
were immediately transferred to surgery. None of the pa-
tients classified as nonresponders by FDG-PET showed a
histopathological response in the resected specimen.
The median survival of those patients was 26 months
which was better than the median survival of 18 months
in a historical control group of nonresponding patients
with the completion of chemotherapy within 3 months.
Thus, there is evidence that nonresponding patients
seem not to be harmed by stopping ineffective chemo-
therapy. However, these results must be interpreted with
caution as data from randomized trials are lacking.
So far, the following methods are available for response
evaluation with varying acceptance: clinical response
evaluation by endoscopy and CT scan during (extremely
rare) or after neoadjuvant chemotherapy [5, 22, 25–27],
histopathological regression of the resected specimen
[23, 28–30], and early response evaluation by FDG-PET
for AEG I and II within a limited number of studies [9,
20, 22, 31, 32]. All the abovementioned methods have
shown significant prognostic relevance in various studies
[9, 20, 22, 28, 32]. However, the most common methods
are clinical and histopathological response evaluation
after completion of chemotherapy or resection. As clin-
ical and histopathological response evaluation after com-
pletion of therapy or resection cannot be used for
therapy stratification, an early clinical response evalu-
ation during treatment is highly warranted.
Response to chemotherapy was first reported to be of
utmost importance for prognosis in gastric cancer in
1999 by Lowy et al. who considered both clinical and
histopathological response evaluation [5]. Response was
either defined clinically by the reduction of more than
50 % in endoscopy, gastrointestinal series, and CT scan
or less than 10 % of residual tumor in the resected speci-
men. Since then, the prognostic relevance for histo-
pathological regression and clinical response has been
confirmed in several studies [6, 19, 28, 30, 33, 34].
Clinical response, defined as nearly total flattening in
endoscopy and more than 50 % reduction in size mea-
sured by endoluminal ultrasound (identical criterion as
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in this study) or CT scan, showed prognostic relevance
in patients with AEG I/II with a median survival of >
53 months in case of response and 13 months in case of
nonreponse (p = 0.01) [22]. In gastric cancer, endoscopic
response evaluation after 50 % of the planned dose of
chemotherapy has been shown to correlate well with the
final histopathological response evaluation and prognosis
in a limited number of patients. All included patients re-
ceived 2 cycles of chemotherapy. After the first cycle of
chemotherapy, the negative predictive value for response
evaluation by endoscopy was 93.9 % and the positive
predictive value was 41.7 % [35]. Consequently, the identi-
fication of nonresponding patients seems reliable in a high
percentage. Therefore and considering the possible harms
of the continuation of a probably ineffective chemother-
apy, the discontinuation of chemotherapy should not be
disadvantageous for patients included in this trial. As data
from a recent study indicate that the length of chemother-
apy does neither influence response, complete resection
rate, nor prognosis of the patients [36], premature termin-
ation of neoadjuvant chemotherapy in nonresponding pa-
tients might be considerably beneficial for patients
regarding prognosis, costs, and quality of life.
Based on the abovementioned data, a clinical response
evaluation after 4 weeks of preoperative chemotherapy
by endoscopy and endoscopic ultrasound seems to be
appropriate to tailor treatment of the nonresponding pa-
tients. Furthermore, as evidence from well-designed
studies is lacking and the critical issue, how to treat non-
responding patients, is still unclear, clinical equipoise is
given within this trial.
A randomized trial is warranted and needed to evalu-
ate the impact of immediate tumor resection in patients
with locally advanced gastroesophageal adenocarcinoma
with nonresponse to chemotherapy to resection after
completion of chemotherapy. A future definitive trial
would be a noninferiority trial aimed at demonstrating
that stopping chemotherapy early and operating sooner
would not lead to a worse outcome. When assuming event
rates of 0.3 in both groups and assuming a noninferiority
margin for the hazard ratio of 0.8, a total sample size of
2100 patients would be necessary, with power of 0.8 and a
level of significance of 0.05 (calculated with Addplan 6.0).
The findings of this current study will give first infor-
mation about clinical response evaluation by endoscopy
and endoscopic ultrasound followed by discontinuation
of neoadjuvant chemotherapy in nonresponding patients.
Based on the results, the possibility to conduct a future
confirmatory trial of high quality will be evaluated with
the aim to prove efficacy and evaluate significance of this
method. Data from this current exploratory pilot trial is
essential in revising the assumptions made in sample
size calculation to determine the required sample size
for a definitive trial.
Trial status
Patient recruitment began in September 2014, and
recruiting of patients is still ongoing.
Endnote
1Pathology records are assessed by a pathological team
specialized on upper gastrointenstinal tumors.
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